Ísland - íslenska - LYFJASTOFNUN (Icelandic Medicines Agency)

sandoz a/s - ceftazidimum inn - stungulyfs-/innrennslisstofn, lausn - 2 g

Ísland - íslenska - LYFJASTOFNUN (Icelandic Medicines Agency)

sandoz a/s - ceftazidimum inn - stungulyfsstofn, lausn - 1 g

Evrópusambandið - íslenska - EMA (European Medicines Agency)

astellas pharma europe b.v. - enfortumab vedotin - carcinoma, transitional cell; urologic neoplasms - Æxlishemjandi lyf - padcev as monotherapy is indicated for the treatment of adult patients with locally advanced or metastatic urothelial cancer who have previously received a platinum-containing chemotherapy and a programmed death receptor 1 or programmed death ligand 1 inhibitor.

Ísland - íslenska - LYFJASTOFNUN (Icelandic Medicines Agency)

fresenius kabi ab - ceftriaxonum dínatríum - stungulyfs-/innrennslisstofn, lausn - 1 g

Ísland - íslenska - LYFJASTOFNUN (Icelandic Medicines Agency)

baxter medical ab* - bleomycinum súlfat - stungulyfs-/innrennslisstofn, lausn - 15.000 a.e.

Ísland - íslenska - LYFJASTOFNUN (Icelandic Medicines Agency)

grünenthal gmbh* - esomeprazolum natríum - stungulyfs-/innrennslisstofn, lausn - 40 mg

Ísland - íslenska - LYFJASTOFNUN (Icelandic Medicines Agency)

laboratorios normon s.a. - cefepimum díhýdróklóríð mónóhýdrat - stungulyfs-/innrennslisstofn og leysir, lausn - 1 g

Ísland - íslenska - LYFJASTOFNUN (Icelandic Medicines Agency)

laboratorios normon s.a. - cefepimum díhýdróklóríð mónóhýdrat - stungulyfs-/innrennslisstofn og leysir, lausn - 2 g

Ísland - íslenska - LYFJASTOFNUN (Icelandic Medicines Agency)

octapharma ab - human fibrinogen - stungulyfs-/innrennslisstofn og leysir, lausn - 1 g

Ísland - íslenska - LYFJASTOFNUN (Icelandic Medicines Agency)

csl behring gmbh* - c1-hemill - stungulyfs-/innrennslisstofn og leysir, lausn - 500 a.e.